mAbMods™ Chimeric Anti-Mouse Antibodies

Reduced Immunogenicity + Muted Effector Functions = Reduced Side Effects

Recombinant antibodies offer many advantages over those produced from traditional hybridoma technology. These include reduced immunogenicity, the ability to mute effector functions to avoid unwanted side effects, and decreased potential for genetic drift. The combination of these factors make recombinant antibodies an excellent choice for pre-clinical *in vivo* functional studies where prolonged and repeated administration of these antibodies is necessary.

mAbMods™ recombinant antibodies have been engineered to have identical antigen binding variable domains to those of the traditional clones from which they are derived, but the IgG constant regions have been engineered to be of mouse origin. This reduces immunogenic responses in the mouse which can lead to adverse immunological reactions and gradual loss of activity.

Fc Muted mAbMods™ recombinant antibodies have engineered mutations (LALA-PG or D265A) in the Fc domain that reduce or eliminate the FcγR binding. This reduces Fc mediated effector functions such as Antibody-Dependent Cellular Cytotoxicity (ADCC), Antibody-Dependent Cellular Phagocytosis (ADCP), and Complement-Dependent Cytotoxicity that can lead to unwanted side effects.

Description	Clone Name	Isotype	Leinco Prod. No.
mAbMods Anti-Mouse CD279 (PD-1)	RMP1-14-mAbMods	Mouse IgG2a	P505
mAbMods Anti-Mouse CD279 (PD-1) - Fc muted™ (LALA-PG)	RMP1-14-mAbMods (LALA-PG)	Mouse IgG2a	P504
mAbMods Anti-Mouse CD279 (PD-1) - Fc muted™ (D265A)	RMP1-14-mAbMods (D265A)	Mouse IgG2a	P503
mAbMods Anti-Mouse TREM2 – Fc Muted™	178 (LALAPG)	Mouse IgG2a	T721

Scan the QR code to see our full catalog of mAbMODs™

Leinco Technologies, Inc.™
excellence in early discovery research™

410 Axminister Dr.
St. Louis, MO 63026
800.538.1145
leincoglobal@leinco.com
www.leinco.com

S01-2307-B